Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer by Ciani, Oriana et al.
1Ciani O, et al. BMJ Open 2019;9:e025483. doi:10.1136/bmjopen-2018-025483
Open access 
Lung Cancer App (LuCApp) study 
protocol: a randomised controlled trial 
to evaluate a mobile supportive care app 
for patients with metastatic lung cancer
Oriana Ciani,1,2 Maria Cucciniello,1,3 Francesco Petracca,1 Giovanni Apolone,4 
Giampaolo Merlini,5 Silvia Novello,6 Paolo Pedrazzoli,5 Nicoletta Zilembo,4 
Chiara Broglia,5 Enrica Capelletto,6 Marina Garassino,4 Elena Nicod,1 
Rosanna Tarricone1,3
To cite: Ciani O, Cucciniello M, 
Petracca F, et al.  Lung 
Cancer App (LuCApp) study 
protocol: a randomised 
controlled trial to evaluate a 
mobile supportive care app 
for patients with metastatic 
lung cancer. BMJ Open 
2019;9:e025483. doi:10.1136/
bmjopen-2018-025483
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
025483).
Received 19 July 2018
Revised 19 December 2018
Accepted 20 December 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr Oriana Ciani;  
 O. Ciani@ exeter. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Mobile health technologies may enhance 
patient empowerment and data integration along the 
whole care continuum. However, these interventions 
pose relatively new regulatory, organisational and 
technological challenges that limit appropriate 
evaluation. Lung Cancer App (LuCApp) is a mobile 
application developed by researchers and clinicians 
to promote real-time monitoring and management of 
patients’ symptoms. This protocol illustrates a clinical 
trial designed to evaluate the usability, effectiveness 
and cost-effectiveness of LuCApp versus standard of 
care.
Methods and analysis This is a 24-week two-arm 
non-blinded multicentre parallel randomised controlled 
trial. A total of 120 adult patients diagnosed with 
small or non-small cell lung cancer and eligible for 
pharmaceutical treatments will be allocated 1:1 to 
receiving either standard care or LuCApp in addition 
to standard care at three oncology sites in Northern 
Italy. During the treatment period, LuCApp allows daily 
monitoring and grading of a list of symptoms, which 
trigger alerts to the physicians in case predefined 
severity thresholds are met. Patients will complete a 
baseline assessment and a set of valid and reliable 
patient-reported outcome measures every 3±1 
weeks, and up to 24 weeks. The primary outcome is 
the change in the score of the Trial Outcome Index in 
the Functional Assessment of Cancer Therapy (Lung) 
questionnaire from baseline to 12 weeks. Secondary 
outcomes are the Lung Cancer Subscale, the EuroQoL 
5D-5L questionnaire, the Hospital Anxiety and 
Depression Scale, the Supportive Care Needs Survey 
Short Form, the app usability questionnaire and the 
Zarit Burden Interview for the main caregiver.
Ethics and dissemination The trial received ethical 
approval from the three clinical sites. Trial results will be 
disseminated through peer-reviewed publications and 
conference presentations.
Conclusions This trial makes a timely contribution 
to test a mobile application designed to improve the 
quality of life and delivery of care for patients with lung 
cancer.
trial registration number NCT03512015; Pre-results.
IntroduCtIon 
The substantial progress made in the diag-
nosis and treatment of cancer entails it can 
be managed as other chronic diseases, where 
long-term active monitoring is needed. In 
order to enhance patients’ quality of life, 
the traditional paternalistic model where 
the patient-provider relationship tends to be 
unilateral and the patient has little say in his/
her care pathway might need to be outclassed 
by new models of care.1 
To this end, self-management interventions 
can help patients and their families care for 
themselves along the cancer care continuum. 
Self-management is here defined as 'the 
individual’s ability to manage the symptoms, 
treatment, physical and psychosocial conse-
quences and life style changes inherent in 
living with a chronic condition’.2 With respect 
to cancer care, patient involvement also 
aims at enhancing symptom management. 
Although recent advances in cancer thera-
pies have led to better clinical outcomes,3 
strengths and limitations of this study
 ► Lung Cancer App (LuCApp) has been designed by 
a multidisciplinary team and developed through 
iterative sessions to improve patients’ real-time 
monitoring of symptoms and side effects during 
pharmacological therapies for lung cancer.
 ► The impact of LuCApp on health-related quality of 
life, cancer supportive care needs, burden for care-
givers and resource consumption will be tested in a 
parallel randomised controlled trial.
 ► Sources of bias may include the different levels of 
ease of participants when using mobile technolo-
gies, the impossibility to blind them and different 
modes of questionnaires administration (app-based 
vs paper/phone-based).
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treatment-related side effects may be significant and 
consequently may have an impact on treatment adher-
ence, frequency of hospitalisations and related costs as 
well as patients’ and their carers’ health-related quality of 
life (HRQoL).
This need for self-management systems together with 
the unsustainability of current healthcare spending has 
witnessed the rapid and ongoing growth in mobile tech-
nologies, including mobile health (mHealth), defined 
as 'medical and public health practice supported by 
mobile devices, such as mobile phones, patient moni-
toring devices, personal digital assistants and other wire-
less devices’.4 As a booming technology, mHealth can be 
instrumental in enhancing patient empowerment and 
patient centricity along the whole care continuum, in 
supporting clinical decision-making, in strengthening the 
data generation process by integrating data from several 
different sources and by connecting stakeholders in the 
healthcare pathway.
However, mHealth products also pose relatively new 
regulatory, organisational and technological challenges 
that need to be tackled in order to ensure appropriate 
evaluation and use.5 6 While there were over 325 000 
mHealth applications (apps) available in major app 
stores and over 3.6 billion downloads in 2017, reflecting 
a growth rate of over 12.5% from the year before,7 overall 
scientific evidence about the effectiveness of mHealth 
apps in improving health-related outcomes is scant.
Few mHealth applications aimed at self-management of 
patients with cancer have been proposed and evaluated. 
Basch et al tested symptom self-reporting during routine 
cancer treatment via Symptom Tracking and Reporting 
against usual care,8 showing a smaller decline in HRQoL 
in the intervention group than in the usual care and, 
in a post hoc analysis, a significant effect on overall 
survival (adjusted HR 0.83, 95% CI 0.70 to 0.99). Denis 
et al compared an e-follow-up application for detecting 
lung cancer relapse with standard surveillance, showing 
improved overall survival for the experimental compared 
with the control arm (HR 0.32, 95% CI 0.15 to 0.67).9 In 
2016, the University of Surrey launched the electronic 
Symptom Management using the Advanced Symptom 
Management System (ASyMS) Remote Technology study, 
a 5-year randomised controlled trial (RCT) conducted 
across five European countries to test the impact of 
ASyMS on patients to commence first-line chemotherapy 
for breast, colorectal or haematological cancer.10
In Italy, several oncologists at ‘Fondazione IRCCS 
Istituto Nazionale dei Tumori’ (Milan) together with 
researchers and software developers initially designed a 
web-based self-management system tailored to the needs 
of patients with cancer. Adjustments were incrementally 
made to refine the application by an extended clinical 
team of researchers at Bocconi University and Advice-
Pharma in order to specifically target patients with lung 
cancer. Lung cancer is the most common oncological 
malignancy and cause of cancer deaths worldwide with 
a total of 1.71 million deaths in 2016.11 The healthcare 
burden and costs attributed to lung cancer is substantial 
and its 5-year survival rate (17.8%) is still much lower 
than that of other leading cancers.12 Because of the signif-
icant impact on HRQoL of lung cancer symptoms and the 
severity of side effects associated with the available phar-
macological treatments for this condition, we believed 
this population was suitable to test an mHealth applica-
tion for self-reporting and management of symptoms and 
treatment-related side effects.
Lung Cancer App (LuCApp) was first made available on 
Playstore (Android online store) and on iTunes (Apple 
online store) in April 2018.
LuCApp has been pilot-tested with a number of oncolo-
gists, healthcare professionals and specialists in palliative 
care from other specialised oncology centres as a mobile 
phone-based remote monitoring system to allow real-time 
gathering of patients’ symptoms and patient-reported 
outcome measures (PROMs) to share with healthcare 
professionals during pharmacological therapies for lung 
cancer.
objECtIvEs
The primary objective of the study will be to determine 
whether LuCApp, by enhancing self-monitoring of ther-
apy-induced side effects compared with the current stan-
dard of care, can lead to increased HRQoL scores as 
measured by the Functional Assessment of Cancer Ther-
apy-Lung (FACT-L) questionnaire13 from the start of the 
pharmacological treatment for lung cancer and up to 12 
weeks (primary end point) and 24 weeks follow-up.
Other secondary objectives of the study will be to eval-
uate the impact of LuCApp during the pharmacological 
treatment for lung cancer and up to 12 weeks and 24 
weeks follow-up from therapy start date on a number of 
outcomes. More specifically, the hypotheses made on the 
impact attainable through the app were:
1. Improved HRQoL as measured by a generic pref-
erence-based measure of health status, EuroQol-5-
Dimensions-5 Level (EQ-5D-5L).14
2. Reduced anxiety and depression as measured by Hos-
pital Anxiety and Depression Scale (HADS),15 a self-as-
sessment scale developed to detect states of depres-
sion, anxiety and emotional distress.
3. Positive impact on patients’ cancer supportive care 
needs vis-à-vis their expectations, as expressed by the 
Supportive Care Needs Survey Short Form (SCNS-
SF34).16
4. Positive impact on caregiver burden in health, psycho-
logical well-being, finances, social life and relationship 
with patient, as measured by the Zarit Burden Inter-
view (ZBI).17
5. Acceptable cost-effectiveness profile of LuCApp versus 
standard care, based on resource use data collected 
throughout the study and quality-adjusted life-years 
(QALY) calculated through EQ-5D-5L on the patient 
population.
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6. Good usability and user satisfaction with LuCApp, as 
assessed by a modified Computer System Usability 
Questionnaire (CSUQ) administered to the patients at 
the end of the study.
study design
This is a 24-week two-arm multicentre parallel RCT 
designed to evaluate the effectiveness, cost-effective-
ness and usability of LuCApp to improve symptoms and 
HRQoL in patients with lung cancer. The protocol has 
been developed in accordance with the Standard Protocol 
Items Recommendations for Interventional Trials State-
ment18 and the Consolidated Standards of Reporting 
Trials of Electronic and Mobile Health Applications and 
online Tele Health checklist.19 The flow diagram for 
recruitment and randomisation is shown in figure 1.
study setting
Patients will be recruited from three oncologic sites in 
Italy: Fondazione IRCCS Policlinico San Matteo (Pavia), 
Fondazione IRCCS Istituto Nazionale dei Tumori 
(Milan), San Luigi Gonzaga Hospital (Orbassano). The 
LuCApp study is led and sponsored by Bocconi Univer-
sity (Milan, Italy) and is registered on  ClinicalTrials. gov 
(NCT03512015). A data management committee was not 
needed as the trial was deemed of minimal risk.20
Participants screening and recruitment
Eligible patients will be identified according to the inclu-
sion and exclusion criteria described in table 1 from 
outpatient and/or inpatient oncology settings at each 
site. Once eligibility has been established, patients will 
be invited to join the study by the local clinical team. 
During the pre-enrolment phase, patients will receive 
an invitation letter, the study leaflet and the informed 
consent form. Patients will be given a sufficient period 
of time to consider participation and they will be advised 
that they can discuss the study with any significant others 
prior to making a final decision. If patients agree to 
participate, written informed consent will be obtained 
during the enrolment visit. At this stage, patients will 
receive adequate training and detailed information about 
the app usage by the research staff, including research 
nurses, data managers and oncologists, who will also help 
patients download the application on their own device. 
Before the arranged appointment for the beginning of 
the therapy, all patients will be asked to fill-in the baseline 
questionnaires on paper.
This is not a purely web-based trial, since face-to-face 
encounters will still be present: patients included in the 
intervention arm will complete follow-up questionnaires 
via the app, while patients in the comparator arm (SoC) 
will complete follow-up paper questionnaires during 
Figure 1 Flow diagram for screening, enrolment, 
randomisation, data collection and analysis. EQ-5D, EuroQoL 
5 Dimensions; FACT-L, Functional Assessment of Cancer 
Therapy-Lung; HADS, Hospital Anxiety and Depression Scale; 
ITT, intention to treat; LuCApp, Lung Cancer App; SCNS-
SF34, Supportive Care Needs Survey Short Form; ZBI, Zarit 
Burden Interview. 
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
 ► Over 18 years of age 
individuals of both sexes.
 ► Diagnosed with small or 
non-small cell lung cancer.
 ► Patients eligible 
for chemotherapy, 
immunotherapy or 
targeted therapy.
 ► Patients diagnosed with 
non-resectable tumour.
 ► Life expectancy of 
6 months or more.
 ► A performance 
status between 0 
(asymptomatic) and 2 
(symptomatic,<50% in bed 
during the day) according 
to the Eastern Cooperative 
Oncology Group score.
 ► Patients fluently speaking 
Italian.
 ► Patients able to provide 
informed consent to 
participate in the study.
 ► Patients who own a 
smartphone that can 
access either the iOS or 
the Android platform.
 ► Individuals unable to 
provide written informed 
consent.
 ► Individuals unable to see 
the app and all other 
materials (ie, are blind).
 ► Patients receiving or 
that plan to receive 
radiotherapy or surgical 
resection as radical 
treatment for the primary 
disease.
 ► Patients already included 
or about to join other 
clinical trials.
 ► Patients already using 
other smartphone 
applications to self-
manage cancer 
symptoms.
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clinic visits or via telephone interviews with the research 
team.
randomisation
Once informed consent has been received and base-
line PROMs collected, the research staff dedicated 
to the recruitment will obtain a randomisation code, 
from randomly permutated blocks stratified by site and 
therapy (ie, chemotherapy, immunotherapy and targeted 
therapy), generated electronically and assigned to the 
patient via a secure web-based electronic case report 
form. The electronic data capture system used for the 
study is validated, secure and redundant and complies 
with standard Food and Drug Administration require-
ments. Standard operating procedures are in place for 
data management process.
The study is non-blinded, as it is not possible to blind 
participants and personnel when this type of interven-
tion and PROMs are under investigation. However, the 
clinician version of LuCApp does not allow the doctors 
to monitor HRQoL questionnaires completed by the 
patients and patients will receive information about 
genuine lack of evidence in relation to the effectiveness 
of the app and will be blinded to study hypotheses. Partic-
ipants will remain into the study until the end of the 
24-week intervention period unless early discontinuation 
occurs due to cessation of cancer treatment, voluntary 
withdrawal or death.
Intervention
Patients assigned to the intervention arm, with the help 
of the local team, will download the app on their mobiles 
and log in by inserting a newly generated custom e-mail 
address and a self-chosen password. Patients assigned to 
this arm will be trained to use LuCApp as a tool for self-re-
porting of lung cancer symptoms and therapies’ side 
effects and PROMs during the enrolment visit. They will 
be assisted during the whole study period by a technical 
‘helpdesk’. Furthermore, the Data Manager will regu-
larly check upload of data from the intervention group 
and, for the purpose of this research only, the research 
team will be in contact approximately biweekly by email 
or phone to verify if there are technical problems and 
to encourage app use. LuCApp is currently at its fifth 
version and we do not anticipate any updating during the 
study period (figures 2–3).
During the study, the use of the app will occur via 
the patient’s own mobile and rely on the usual network 
connectivity. Patients will be required to log in when-
ever they access the application: this will guarantee that 
validated data are collected and that only patients can 
access to sensitive data. The Android and iOS versions of 
the app (patient version) serve as a data capture inter-
face that collects and transfers data, under https secu-
rity protocol, to the database behind the electronic data 
capture platform. Patients will not be compensated (by 
cash or in-kind) for their participation in the trial, nor 
will they be asked to pay for the app, which will be freely 
available for download.
The intervention presents several different and unique 
functionalities and components that were designed to aid 
symptom self-reporting and management:
Figure 2 Lung Cancer App (LuCApp) patient version. Home screen where the patient can access self-monitoring, info and 
questionnaires; example of daily symptom questionnaire and health-related quality of life visual analogue scale.
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"How do I feel today?" This component of the app 
allows participants to fill in a questionnaire to report their 
daily situation with respect to side effects commonly expe-
rienced during therapies for lung cancer and identified 
from the literature.21–24 From an initial list of 68 symp-
toms, 2 teams of lung cancer specialists checked those 
symptoms that they consider relevant for the patient 
population under investigation and cross-validated the 
respective selection to arrive to a final list of 22 items. 
Symptoms will be rated on a scale from 0 to 4 (where 0 is 
symptom not present, 4 is maximum degree of severity). 
Questions were adapted for patient use from the National 
Cancer Institute’s Common Terminology Criteria for 
Adverse Events (CTCAE).25 LuCApp will trigger alerts to 
healthcare professionals whenever a symptom of level ≥3 
is inserted. Patients will be aware that reporting symp-
toms above that threshold will produce an alert to the 
clinicians: in order to elicit truthful answers, for each 
symptom we included a detailed description and a set of 
options with specific criteria referred to the exact grade 
listed in the CTCAE.
Although compilation is possible several times per day, 
patients will receive a reminder (as a mobile banner or 
email) to fill in this questionnaire every 3 days. Up to 
three different reminders will be sent at 12:00, 18:00 and 
21:00 hours to encourage patients to self-report their 
symptoms using a recall period of the past 24 hours. 
Symptom reports will be available to clinicians only.
 ► ‘Temperature’ and ‘weight’—patients in the LuCApp 
arm will be asked to enter their body temperature 
daily and their weight once per week again via mobile 
banners or emails. Patients will be advised to enter 
their daily body temperature at similar times each day 
and to use the same scale to measure their weight. 
Whenever body temperature exceeds the 38°C or a 
5% reduction in body weight over two consecutive 
weeks is observed, specific alerts will be generated to 
inform the clinical team.
 ► ‘Tip of the day’—whenever a patient logs into the 
app, a daily tip, a short suggestion to better manage 
the side effects of the therapies, is shown. Tips were 
drawn from clinical practice guidelines and discussed 
by a consensus group of experts including medical 
oncologists, radiation oncologists, surgeons, nutri-
tionists, speech language pathologists, infectious 
disease specialists, dentists and nurses.26 27
 ► ‘Questionnaires’—this section allows patients to fill-in 
several PROMs about their HRQoL and experience 
with supportive care needs and LuCApp: EQ-5D-5L, 
FACT-L, HADS, SCNS-SF34, usability and satisfaction 
questionnaire.
 ► ‘Info’—in order to increase the overall patient’s 
awareness about his/her condition and management 
options, this section collates relevant educational 
material such as general information on lung cancer, 
therapies, patients’ rights, useful institutional links.
As a direct consequence, although the inclusion of 
targeted therapies as well as chemotherapies may imply 
that some patients will be undergoing oral treatments at 
home and not in hospitals or clinics, the app does not aim 
at managing, at least not directly, medication adherence.
Continuity in the utilisation of the app will be strongly 
recommended and encouraged by automated reminders 
when the data input is scheduled.
Figure 3 Lung Cancer App (LuCApp) clinician version. Home screen and examples of actions taken in response to alerts.
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Through LuCApp, clinicians will receive alerts on their 
dedicated LuCApp device (ie, smartphone, laptop) and 
will be required to respond within 24 hours and document 
the type of intervention performed (eg, referral to the 
emergency room/hospital, telephone counselling about 
symptom management, dose modification, supportive 
medication initiation/change, visit anticipation).8 In the 
healthcare professional app only, clinicians can view the 
longitudinal trend of their patients’ clinical parameters. 
Side effects, temperature and weight are displayed in 
charts over a timeframe of choice.
Healthcare professionals will be trained through dedi-
cated sessions prior to the launch of the study. Contact 
details of LuCApp developers and technicians will be 
provided for assistance. However, if the technology does 
not function properly and the clinician believes an action 
is urgently needed for a patient, the research team is 
advised that standard of care applies to the intervention 
arm, too. During weekends or national holidays, it is 
possible that clinicians will not be reachable or will not 
reply promptly to alerts. Also in this case patients are 
advised to use the standard of care approach (eg, out-of-
hours service doctor, emergency department).
standard of care
Standard of care in this setting consists of procedures 
currently available at participating centres for monitoring 
and documenting treatment-related symptoms in patients 
with lung cancer and aligned with the guidelines devel-
oped by the Italian Association of Medical Oncology.28 
Participating centres are either research dedicated hospi-
tals (San Matteo Hospital, Istituto Nazionale Tumori) 
or teaching hospital (San Luigi Gonzaga Hospital). 
Symptoms for control arm patients will be discussed and 
registered during scheduled clinical visits with the oncol-
ogists. Patients are usually allowed to contact their sites 
for concerning symptoms that occur between scheduled 
visits or advised to see the out-of-hour doctor. An emer-
gency department is available at San Matteo Hospital and 
San Luigi Gonzaga Hospital, but not at Istituto Nazio-
nale Tumori. PROMs will be filled in following the same 
schedule identified for LuCApp patients with paper ques-
tionnaires during clinic visits or via telephone interviews 
with the research team.
outcomes
As part of this RCT, LuCApp will be evaluated in terms of 
impact on: (1) HRQoL, (2) cancer supportive care needs, 
(3) burden for caregivers, (4) resource use, (5) usability 
and patients’ satisfaction. The rationale for selecting these 
measures and their characteristics are detailed below.
Health-related quality of life
The selection of HRQoL measures was based on the avail-
ability of a validated Italian version of the tool, for self-re-
port use, that can be administered both on paper and via 
smartphones, and commonly used in patients with lung 
cancer.
Symptoms are subjective experiences self-reported by 
the patient, and are a subset of patient perceptions of 
health status and HRQoL.29 HRQoL is a multidimen-
sional construct of diverse functional scales (eg, physical 
function, psychological function, social role function) 
and symptom scales (eg, disease-related or treatment-re-
lated symptoms). Three questionnaires were selected.
a. FACT-L questionnaire is a disease-specific measure 
capturing multidimensional aspects of quality of lives 
of patients with lung cancer.13 The symptoms covered 
are shortness of breath, weight loss, consciousness, 
cough, hair loss, appetite, tightness in chest, breath-
ing. FACT-L is the result of the combination of FACT-G 
(general module and core instrument), which is a 
general quality of life questionnaire for use in a vari-
ety of chronic illness conditions, with a Lung Cancer 
Subscale (LCS). Evidence suggests that while there are 
small differences in the way people respond based on 
mode of administration (ie, in-person or telephone/
in the clinic or by mail/computer administered), these 
alternate formats are essentially equivalent, particular-
ly when reporting data at the group level.30 The ques-
tionnaire will be administered at baseline, at 12 weeks 
and at the end of the study period.
b. EQ-5D-5L is a generic preference-based measure of 
health status, which is the most commonly used tool 
used to derive utility values that can be used within an 
economic evaluation model.14 This tool is also com-
monly used in lung cancer trials.31 It includes 5-level 
questions covering five domains: mobility, self-care, 
usual activities, pain and discomfort and anxiety and 
depression. Additionally, patients are asked to fill in 
how they feel today on a vertical visual analogue scale. 
The questionnaire will be administered at baseline, ev-
ery 3±1 weeks to take into account that visit intervals 
may vary between patients and across therapies, and at 
the end of the study period.
c. HADS is a self-assessment scale developed to detect 
states of depression, anxiety and emotional distress 
among patients treated for a variety of problems in the 
setting of outpatient clinics.15 It is composed of two 
7-item scales for depression and anxiety, respectively. 
HADS was identified as one of the most commonly 
used PROMs in advanced-staged lung cancer clinical 
trials of pharmaceutical agents,32 and has been used to 
measure HRQoL in patients with non-small cell lung 
cancer.33 Literature shows HADS is a reliable and valid 
tool to identify patient with emotional disorders.34 The 
questionnaire will be administered at baseline, at 12 
weeks and at the end of the study period.
Cancer supportive care needs
Patients with lung cancer have greater unmet supportive 
care needs than patients with other cancer.35 The 
supportive care needs survey, short form (SCNS-SF34) is 
a needs assessment questionnaire in cancer supportive 
care measuring the gap between patients' experience and 
their expectations.36 37 It consists of 31 items covering 4 
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domains: psychological needs, health system and infor-
mation needs, physical and daily living needs and patient 
care and support needs. For each question, patients are 
asked to provide an indication of their level of need on a 
5-point Likert scale.37 There is still not evidence that the 
SCNC-SF34 is responsive to change over time; however, 
this is currently being tested in an ongoing longitudinal 
study.37 The SCNS-SF34 is available on LuCApp for the 
intervention group and will be administered at the end 
of study to assess whether supportive care needs were 
fulfilled in the different study arms.
Burden on caregivers
The ZBI is a 22-item self-administered scale measuring 
caregiver burden in health, psychological well-being, 
finances, social life and relationship with patient. Each 
item is measured on a 5-point Likert scale. The total 
burden is obtained by adding the scores across all 22 
items: the higher the score, the higher the burden. The 
ZBI has been widely referenced in studies measuring 
caregiver burden of patients with cancer.38 39
Assessment timing of the ZBI will be at the end of the 
study, and will be administered in paper format or via 
phone.
Usability and satisfaction of LuCApp
Patients in the intervention arm will have an opportu-
nity to provide feedback on strengths and shortcomings 
of the application, including unintended/unexpected 
effects. Use and adoption metrics are important process 
outcomes to understand the mechanism of action of such 
intervention. The mHealth application contains a tracking 
system. Frequency and duration of logins and the activity 
will be recorded and evaluated. To test user satisfaction 
with the app, a modified CSUQ will be administered to 
both patients and clinicians using LuCApp. The CSUQ is 
an overall satisfaction questionnaire that was developed 
together with other subjective usability measures at IBM 
in the 90s.40 The CSUQ was later adapted for mobile apps 
usability testing to elicit participant satisfaction with the 
PAediatric Risk Assessment app, a mHealth tool devel-
oped to help healthcare professionals in resource-limited 
settings detect patients at high risk of both in-hospital and 
postdischarge mortality.41 The final version consists of 12 
items evaluated on a Likert scale. In addition, three qual-
itative questions were added to draw further information 
on the application and on the generalisability of LuCApp 
in the current and other clinical contexts: (1) "‘What 
do you like the most about the app?”; (2) "What do you 
like the least about the app?"; (3) "How could the app be 
changed to make it easier to use?". The questionnaire will 
be administered at the end of the study.
Resource use
Resource use will be captured through patients’ reports 
of symptoms and clinicians' actions in response to those 
symptoms (eg, prescriptions, hospitalisations including 
emergency access, change in therapy). Moreover, 
additional information will be obtained for both control 
and treatment group patients via a form administered 
during the clinics on instrumental and diagnostics tests 
performed, general practitioner or specialist visits, addi-
tional medicines or dietary supplements taken, hospi-
talisation or emergency access occurred between visits. 
Average per-patient clinician time spent for LuCApp 
management, including troubleshooting or reminder 
contacts established with the patients, or standard care 
management of lung cancer therapies’ symptoms will be 
elicited with questionnaires administered to the clinicians 
at different time points during the study.
study close-out
At study close-out at week 24, patients in the intervention 
arm will not continue to use the app and will be lead back 
to standard of care. They will fill all PROMs in through 
the app, while for standard of care patients PROMs will be 
collected in the hospital during an ad hoc closing visit. As 
for the ZBI, which will be administered to the main care-
giver at the end of the study, it will be completed either in 
person or via phone.
sample size calculation
The change in the Trial Outcome Index (TOI) of the 
FACT-L questionnaire from baseline to 12 weeks was used 
as primary end point for this study. FACT-L questionnaire 
contains four general and one lung cancer symptom-spe-
cific subscales. General subscales include: Physical Well-
Being (PWB), Social/family Well-Being, Emotional 
Well-Being and Functional Well-Being (FWB).42 The LCS 
assesses symptoms commonly reported by patients with 
lung cancer (eg, shortness of breath; loss of weight; tight-
ness in chest). The TOI is derived by adding scores on 
the PWB and FWB subscales to the LCS. Because they 
contain the most relevant questions about symptoms and 
physical functioning, the LCS and TOI were selected as 
the primary focus of this analysis. All FACT-L questions 
are rated on 5-point Likert-type scales ranging from 0 
(‘not at all’) to 4 (‘very much’). TOI scores range from 
0 to 84 where higher scores represent better HRQoL or 
fewer symptoms. After accounting for about 20% attrition 
rate, we estimated that with 120 patients allocated 1:1 
between LuCApp and usual care groups, the study would 
have 90% power with a two-sided α of 0.05 to detect a 
significant between-group difference of 5 points43 in the 
change in the TOI score from baseline to 12 weeks, given 
a pooled SD of 15.44
data analysis plan
Baseline demographic and clinical characteristics will 
be tabulated by treatment groups and descriptive statis-
tics will be provided. For the primary HRQoL end point 
of changes from baseline in FACT-L TOI 12 weeks after 
randomisation, a repeated-measures analysis using mixed 
models to test the difference between LuCApp and stan-
dard care groups will be performed, adjusting for baseline 
values and characteristics, pharmacological treatment, 
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site and length of treatment. The proportion of patients 
in each arm who experienced improved, unchanged or 
worsened scores from baseline will be compared using χ2 
or Fisher’s exact test. This analysis will be run for both 
any change and clinically meaningful changes for specific 
subscales.43 For all other questionnaires, changes from 
baseline, or follow-up values only, in the LuCApp group 
and in the control group at 12 and 24 weeks after rando-
misation will be computed and compared. Repeated 
measures of the outcomes will be analysed again with 
mixed models adjusted for relevant covariates, as with the 
primary end point, up to 24 weeks.
Analysis of missing data will first determine how 
common a problem this is and whether it can be assumed 
to be missing at random or not missing at random. 
Multiple sensitivity imputation analyses will be conducted, 
including last observation carried forward, minimum 
observation values carried forward, average observation 
values carried forward and multiple imputation. EQ-5D 
value will be set to zero if death occurs before 6 months. 
Survival time will be calculated from the date of enrol-
ment to the date of death or censoring those alive at the 
last follow-up with the use of the Kaplan-Meier method. 
A Cox proportional hazards model will be fitted to assess 
the effect of LuCApp on survival, with adjustment for 
demographic characteristics and baseline performance 
status. Primary analyses will be based on the intention-
to-treat principle. Secondary per-protocol analyses will be 
performed taking into account use and adoption metrics 
available through the app embedded tracking system.
By combining EQ-5D-derived utilities and survival, 
QALY for participants in both arms will be computed 
and compared using two group t-tests between LuCApp 
and standard care arm. A multivariable linear regression 
model with QALY as dependent variable will be used to 
adjust for other covariates. Resource consumption and 
related costs will be calculated and reported for each 
treatment group and compared by means of parametric 
and non-parametric tests.45 The perspective taken for 
the evaluation of resource consumption will be that of 
the National Healthcare System. Unitary costs will be 
expressed as EUR 2018. Drug unitary costs will be derived 
from national price listings, visits, laboratory and instru-
mental tests, will be valued according to the outpatient 
procedures formulary, while hospitalisations and emer-
gency access will be valued according to tariffs and special 
funding mechanisms in place in Lombardy Region.
Two-sided p values of <0.05 will be considered to indi-
cate statistical significance. All statistical analyses will be 
performed using STATA V.14.2 (StataCorp, Texas, USA).
Patient and public involvement
A panel of patients with cancer was involved via focus 
group in the development of LuCApp. A lay summary of 
study results will be prepared and made available online 
and at the three oncology sites. A battery of patient-re-
ported outcomes will be collected to assess the burden of 
the intervention.
Ethics and dissemination
Any major study protocol amendments will be submitted 
to the following three clinical sites: Fondazione Istituto 
di Ricovero e Cura a Carattere Scientifico (IRCCS) Poli-
clinico San Matteo, Fondazione IRCCS Istituto Nazio-
nale dei Tumori and Azienda Ospedaliero-Universitaria 
San Luigi Gonzaga. Study-related adverse events will be 
reported to the Italian competent authority and to the 
local ethics committees. Trial results will be disseminated 
through publications in scientific journals and presenta-
tions at national and international conferences.
ConClusIons
The electronic health and mhealth revolution holds great 
potential for improving symptom management strategies 
in chronic conditions. With spending review reforms 
under way, using web-based and mobile-based tech-
nology to develop low cost and pragmatic patient-cen-
tred intervention is key to lessening the healthcare costs 
and advancing the science of symptom management. In 
parallel with the development of new strategies and prod-
ucts, the evaluation of such interventions becomes critical 
in order to bring to patients and to healthcare systems 
effective and cost-effective solutions. LuCApp trial is now 
open and recruiting to test the usability, effectiveness and 
cost-effectiveness of a new mobile technology to improve 
the management of symptoms and side effects in patients 
undergoing pharmaceutical treatments for lung cancer. 
Compared with previous trials, LuCApp has a focus on 
this specific solid tumour while allowing for monitoring 
of patients treated with different pharmaceutical thera-
pies, including newly approved immunotherapy agents 
whose safety and effectiveness evidence is progressively 
increasing.46 Inclusion of patients confident with the use 
of mobile technologies as well as impossibility of blinding 
participants may represent potential sources of bias in 
this study. While this might influence recruitment speed 
and generalisability of results to mobile device non-users, 
a greater likelihood that patients will use the device more 
frequently is guaranteed.47 Moreover, different modes 
of questionnaires administration (app-based vs paper/
phone-based) may result in different response rates and 
missing data across the two arms, although monitoring of 
outcomes collection at prespecified time points will occur 
for both intervention and control groups.
Although conducting mHealth research with mobile 
phones is complex, this is a promising field to create tools 
that can have meaningful impact on the lives of people 
and delivery of care. This trial will be a timely opportu-
nity to test and address the challenges unique to a mobile-
based application to improve the HRQoL of patients with 
a lung cancer condition.
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